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Tilburg University, Faculty of Social Sciences, Tilburg, Netherlands‘If I can’t feel, if I can’t move, if I can’t think, and I can’t care,
then what conceivable point is there in living?’(Kay Redfield Jamison, An Unquiet Mind: A Memoir of
Moods and Madness)
Mood is a person’s subjective emotional state. According to
the DSM-IV the term mood disorder is used for a group of
diagnoses where the primary symptom is a disturbance in
mood, or in other words the experience of an inappropriate,
exaggerated or limited range of feelings. Mood disorders can
mainly be divided into two groups: (1) depressive episode(s)
characterised by feelings of sadness, hopelessness, helpless-
ness, guilt, suicidal thoughts, fatigue, appetite changes, con-
centration problems and troubles engaging in daily living
tasks; (2) manic or hypomanic episode(s) characterised by
feelings of grandiosity, extreme energy and heightened arou-
sal. Several treatment options are available for mood disor-
ders – e.g. medication, cognitive and/or behavioural therapy
– depending on the severity and the evaluation of the
health-care provider.
Several studies have shown that mood disorders are com-
mon in patients with cancer. In a meta-analysis, the point
prevalence of major depression was about 16% and that of
anxiety was 10% [1]. The exact causes of mood disorders are
largely unknown, but it is hypothesised that an imbalance
in neurotransmitters is likely to play a role. The mood disor-
der can be triggered by the cancer diagnosis on its own, or it
can be treatment-induced in cases where the aetiology can
be found in the physiological effect of a psychoactive drug
or chemical substance.
These articles provide an overview of the most common
mood disorders among cancer patients. First, Dr. Dauchy willdiscuss the prevalence, predictive factors and treatment op-
tions of depression, one of the most under-diagnosed and
inadequately treated mood disorders among cancer patients.
Second, Professor Caraceni will introduce drug-associated
delirium, an altered state of consciousness with reduced
awareness of self and the environment, which may go hand
in hand with the inability to think and talk clearly and ratio-
nally, hallucinations, disorientation and cognitive impair-
ment. Third, Dr. Die Trill will discuss anxiety, one of the
most frequently reported reactions to a cancer diagnosis,
whichmay persist throughout the cancer continuum. In addi-
tion, she will shine her light on sleep disorders, which are fre-
quently associated with psychological disorders. Finally, Dr.
Schagen will describe the chemotherapy-related changes in
cognitive functioning, which can result in diminished func-
tional independence and can last throughout the survivorship
period.
Conflict of interest statement
None declared.R E F E R E N C E[1] Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression,
anxiety, and adjustment disorder in oncological,
haematological, and palliative-care settings: a meta-analysis
of 94 interview-based studies. Lancet Oncol 2011;12:160–74.
